Expert Interview
Second View: Discussing Novo Nordisk's recent Phase 2 trial results on Monolunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, in the treatment of obesity.
Ticker(s): NVO- Originally from Ecuador.
- Completed her PhD at Pontifical Catholic University.
- Completed her MD at University of Pittsburg Medical Clinic.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
